8-K: Hyperliquid Strategies Completes Sonnet BioTherapeutics Merger

Hyperliquid Strategies Inc. (HSI) has completed its business combination with Sonnet BioTherapeutics Holdings, Inc., with HSI common stock set to trade on Nasdaq under 'PURR'.

Summary

• Hyperliquid Strategies Inc. (HSI) has completed its previously announced business combination with Sonnet BioTherapeutics Holdings, Inc. (Sonnet) and Rorschach I LLC.
• Sonnet will now operate as a wholly-owned subsidiary of HSI, which will function as a HYPE digital asset treasury reserve company.
• HSI's common stock is expected to begin trading on The Nasdaq Capital Market under the ticker symbol 'PURR' on December 3, 2025, while Sonnet's common stock will cease trading.
• Sonnet shareholders received one-fifth of one share of HSI common stock and one contractual contingent value right (CVR) for each share of Sonnet common stock.
• Rorschach contributed at least $200,000,000 in HYPE Tokens Value (valued at $46.372 per token) and potentially additional cash/cash equivalents to HSI.
• A private placement (PIPE) was consummated immediately prior to closing, where 239,921,355 shares of Sonnet Common Stock were purchased at $1.25 per share, then converted into HSI shares and CVRs.
• The combined cash and cash equivalents from the Contribution and Financings (Bridge and PIPE) met the minimum cash amount of $50,000,000.
• Sonnet's stockholders approved the business combination, an equity incentive plan, and an amendment to increase authorized common stock to 500,000,000 shares.

Sentiment

Score: 7

Explanation: The sentiment is positive due to the successful completion of a significant strategic business combination, the new company's clear focus on a high-growth digital asset sector, and positive management commentary. The CVRs offer potential upside for former Sonnet shareholders. However, inherent risks associated with the volatile digital asset market and the speculative nature of CVRs temper the overall score.

Positives

• The successful completion of the business combination provides U.S. equity investors with direct exposure to the HYPE token and the Hyperliquid ecosystem.
• Hyperliquid is described as a market leader in perpetual futures and spot trading, processing billions in daily trading volume, indicating strong underlying asset performance.
• The new entity, HSI, aims to maximize shareholder value through a capital-efficient digital asset treasury strategy, including staking, yield optimization, and active ecosystem engagement.
• The CVRs offer Sonnet shareholders potential future value from Sonnet's legacy drug development programs (SON-1010, SON-1210, SON-1400, SON-1411, SON-080).

Negatives

• Sonnet BioTherapeutics Holdings, Inc. common stock will be delisted from Nasdaq and will no longer trade, potentially impacting liquidity for former Sonnet shareholders.
• The CVRs are highly speculative and subject to numerous factors outside of PubCo's control, with no assurance that holders will ever receive payments.

Risks

• Changes in business, market, financial, political, and regulatory conditions could adversely affect HSI's operations.
• The price of HSI's stock is expected to be highly correlated to the highly volatile price of HYPE tokens, which may decrease.
• There is significant legal, commercial, regulatory, and technical uncertainty regarding HYPE tokens and crypto assets.
• Risks exist related to the treatment of crypto assets for U.S. and foreign tax purposes.
• HSI may experience difficulties managing its growth and expanding operations.
• Challenges in implementing HSI's business plan, including HYPE token-related financial and advisory services, due to operational challenges, significant competition, and regulation.
• The CVRs are contractual rights and do not constitute equity or a security of PubCo, and there is no assurance of any CVR payments.

Future Outlook

HSI's primary focus is to maximize shareholder value by accumulating HYPE, the native token of the Hyperliquid blockchain, through a digital asset treasury strategy. This strategy aims to provide capital-efficient access to the HYPE token for U.S. and institutional investors, generating compounding shareholder returns through staking, yield optimization, and active ecosystem engagement. The company is positioned to capitalize on Hyperliquid's rapid growth and revenue pools in digital assets. Sonnet will continue its oncology-focused biotechnology operations as a subsidiary, with potential future value for CVR holders from its legacy drug development programs.

Management Comments

• Bob Diamond, Chairman of HSI: "We are thrilled to have completed this business combination, allowing US equity investors to gain exposure to the HYPE token through our digital asset treasury strategy with a large, highly liquid listing."
• David Schamis, CEO of HSI: "The Hyperliquid blockchain was built to house all finance. It has rapidly become one of the highest-revenue-generating blockchains in the world. The Hyperliquid decentralized exchange is a market leader in perpetual futures and spot trading that is used by hundreds of thousands of traders around the world, processing billions in daily trading volume. Today marks a watershed moment: U.S. public market investors can now participate directly in the Hyperliquid ecosystem and do so through a highly liquid, publicly traded vehicle."
• Alana Palmedo, Paradigm Managing Partner: "Hyperliquid's approach to high-performance, decentralized trading has attracted substantial volumes from a growing community of traders and developers. Hyperliquid Strategies provides an innovative vehicle for investors to gain exposure to this emerging network."

Industry Context

This business combination represents a significant strategic shift for Sonnet, moving from a pure-play oncology biotechnology company to a subsidiary under a new digital asset treasury company, HSI. The transaction allows HSI to leverage the public market listing to provide U.S. and institutional investors with exposure to the rapidly growing Hyperliquid blockchain ecosystem and its native HYPE token. This aligns with a broader trend of traditional financial markets seeking avenues to participate in the digital asset space, particularly in high-performance decentralized finance (DeFi) protocols. The move positions HSI to capitalize on the increasing institutional interest in crypto assets and the potential for yield generation within these ecosystems, while Sonnet's biotech assets are spun off into CVRs, reflecting a potential de-risking or monetization strategy for its legacy pipeline.

Comparison to Industry Standards

• Hyperliquid is highlighted as a market leader in perpetual futures and spot trading, processing billions in daily trading volume, suggesting strong competitive positioning within the decentralized exchange (DEX) sector.
• The strategy of providing capital-efficient and productive access to a native token (HYPE) for U.S. and institutional investors through a publicly traded vehicle is an innovative approach to bridge traditional finance with the digital asset industry, similar to other publicly traded vehicles that hold or provide exposure to cryptocurrencies like Bitcoin or Ethereum, but specifically focused on a high-performance Layer 1 blockchain.
• The formation of HSI as a 'digital asset treasury reserve company' with a focus on 'staking, yield optimization, and active ecosystem engagement' positions it against other crypto investment funds or trusts, aiming for compounding shareholder returns that individual holders might not replicate.

Management Changes

Corporate Governance

Related Party Transactions

• Rorschach I LLC, a newly-formed entity affiliated with Atlas Merchant Capital LLC (Atlas), an affiliate of Paradigm Operations LP (Paradigm), and additional sponsors, is a party to the business combination.
• David Schamis, CEO of HSI, is also associated with Atlas Merchant Capital LLC.
• Bob Diamond, Chairman of HSI, is a founder of Atlas Merchant Capital LLC.

Stakeholder Impact

• **Shareholders (Sonnet)**: Former Sonnet shareholders now hold HSI common stock and CVRs, transitioning their investment from a biotech company to a digital asset treasury company with a biotech subsidiary. This represents a significant change in investment profile and risk.
• **Shareholders (HSI/Rorschach)**: Rorschach members receive HSI common stock, gaining a public listing for their digital asset strategy. New HSI shareholders gain exposure to the HYPE token and the Hyperliquid ecosystem.
• **Employees (Sonnet)**: Key management changes occurred at Sonnet, with several officers and directors resigning. Raghu Rao remains CEO and sole director of the Sonnet subsidiary. The impact on other employees is not explicitly detailed but a change in ownership and strategic focus could lead to operational adjustments.
• **Customers/Partners (Sonnet)**: Sonnet's drug development programs continue under the HSI umbrella, with CVRs tied to their monetization. The long-term impact on existing partnerships or future drug development is subject to HSI's strategic decisions and the commercial viability of the assets.
• **Creditors**: The business combination and associated financings (PIPE, Bridge, Contribution) alter the capital structure and financial health of the combined entity, which could impact creditors' risk assessment.

Next Steps

• HSI's common stock (PURR) is expected to begin trading on The Nasdaq Capital Market on December 3, 2025.
• Nasdaq will file a notification of removal from listing and deregistration of Sonnet Common Stock on Form 25 with the SEC.
• Sonnet intends to file a Form 15 with the SEC to request deregistration of its common stock and suspension of reporting obligations.
• PubCo and the Rights Agent will execute and deliver the CVR Agreement.
• PubCo will continue to use commercially reasonable efforts to develop Company Legacy Assets and pursue Company Legacy Transactions during the CVR Term, subject to certain conditions and discretion.

Key Dates

Keywords

Hyperliquid Strategies Inc, Sonnet BioTherapeutics Holdings Inc, Business Combination, Merger, HYPE token, Digital Asset Treasury, Nasdaq Listing, PURR, SONN, Contingent Value Rights, CVR, Biotechnology, Oncology, Crypto Assets, SEC Filing, Corporate Governance